Results 91 to 100 of about 2,631,955 (205)

Tumor Mutation Burden in lung cancer

Annals of Oncology, 2019
Abstract The clinical success of PD-1 pathway-targeted immunotherapy in a subset of lung cancer patients is imperfectly predicted by PD-L1 expression alone. Very unlike the targeting of activating driver mutations, PD-L1 represents a continuous variable that is semi-quantitatively assessed currently by immunotherapy and only relatively enriches for ...
openaire   +1 more source

Image_4_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.TIFF

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

DataSheet1_Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers.xlsx

, 2022
Ovarian cancer (OC), one of the most common malignancies of the female reproductive system, is characterized by high incidence and poor prognosis. Tumor mutation burden (TMB), as an important biomarker that can represent the degree of tumor mutation, is ...
Siyuan Shen (649230), Hua Jin (320594), Mengjing Cui (3125808), Wenjing Yan (1918651), Xing Zhang (11943), Shuqian Xie (11101006), Dan Meng (124143), Qianqian Xia (708901), Shizhi Wang (337117)   +8 more
core   +1 more source

Data_Sheet_1_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.xlsx

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

Chris Burden 74-77

, 1978
Presentation of 31 performances by Chris Burden performed from 1974 to 1977, with notes by the ...
Burden, Chris
core   +1 more source

Tumor mutational burden as predictive factor of response to immunotherapy

Translational Lung Cancer Research, 2018
In May 2018, Hellmann et al . published in Cancer Cell journal a retrospective study analyzing the predictive value of tumor mutational burden (TMB) in 75 non-small cell lung cancer (NSCLC) patients treated with the combination of the anti PD-1 inhibitor nivolumab and the anti CTLA-4 antibody ipilimumab in the Check-Mate 012 study.
Maria, Gonzalez-Cao, Santiago, Viteri, Niki, Karachaliou, Andres, Aguilar, Juan Jose, García-Mosquera, Rafael, Rosell   +5 more
openaire   +3 more sources

Image_9_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.TIFF

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

Image_6_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.TIFF

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

Image_3_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.TIFF

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

Integrative epigenetic and genetic pan-cancer somatic alteration portraits

Epigenetics, 2017
Genetic and epigenetic alterations are required for carcinogenesis and the mutation burden across tumor types has been investigated. Here, we investigate epigenetic alterations with a novel measure of global DNA methylation dysregulation, the methylation
Lucas A. Salas, Kevin C. Johnson, Devin C. Koestler, Dylan E. O'Sullivan, Brock C. Christensen   +4 more
doaj   +1 more source